April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Intereye Relationship in Rates of Retinal Nerve Fiber Layer Loss in Glaucoma
C. Rodarte; L. M. Alencar; L. M. Zangwill; C. Bowd; P. A. Sample; R. N. Weinreb; F. A. Medeiros
Author Affiliations & Notes
  • C. Rodarte
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
  • L. M. Alencar
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • L. M. Zangwill
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
  • C. Bowd
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
  • P. A. Sample
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
  • R. N. Weinreb
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
  • F. A. Medeiros
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  C. Rodarte, None; L.M. Alencar, None; L.M. Zangwill, Carl Zeiss Meditec, Inc., F; Heidelberg Engineering, GmbH, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; C. Bowd, Lace Elettronica, F; P.A. Sample, Carl Zeiss Meditec, F; Haag-Streit, F; Welch-Allyn, F; R.N. Weinreb, Carl Zeiss Meditec, Inc., F; Heidelberg Engineering, GmbH, F; Novartis, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Carl Zeiss Meditec, Inc., C; Glaxo, C; Optovue, Inc., C; Pfizer, Inc., C; Topcon Medical Systems, Inc., C; F.A. Medeiros, Carl-Zeiss Meditec, F; Alcon, Inc, F; Pfizer, Inc, F; Allergan, Inc, C; Alcon, Inc, C; Pfizer, Inc, C; Carl-Zeiss Meditec, R; Allergan, Inc, R; Alcon, Inc, R; Pfizer, Inc, R; Reichert, Inc, R.
  • Footnotes
    Support  NEI EY11008 (LMZ), NEI EY08208 (PAS), and participant retention incentive grants in the form of glaucoma medication at no cost from Alcon Laboratories Inc, Allergan, Pfizer Inc, and Santen Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4018. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Intereye Relationship in Rates of Retinal Nerve Fiber Layer Loss in Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      C. Rodarte, L. M. Alencar, L. M. Zangwill, C. Bowd, P. A. Sample, R. N. Weinreb, F. A. Medeiros; Intereye Relationship in Rates of Retinal Nerve Fiber Layer Loss in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4018.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the intereye relationship in rates of progressive retinal nerve fiber layer thickness (RNFLT) loss in glaucoma.

Methods: : The study included both eyes of 144 glaucoma and glaucoma suspect patients recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) with a median follow up of 2.61 (±0.81) years. Images were obtained annually using the GDx with enhanced corneal compensation along with optic nerve head stereophotographs and standard automated perimetry (SAP) visual fields. Progression was determined for each eye by masked review of optic nerve head stereophotographs and/or a "likely progression" result on the Guided Progression Analysis software for SAP. Joint multivariate mixed models were used to evaluate rates of GDx measured RNFLT loss in both eyes of each subject and the intereye association.

Results: : There was a strong correlation in the rates of RNFLT loss between the right and left eyes of glaucoma and glaucoma suspect patients followed over time (r = 0.83; P < 0.001). During follow-up, 25 (17%) patients showed progression with stereophotographs and/or SAP. Of these, 24 showed progression by conventional methods in only one eye. Comparing both eyes of these 24 patients showed that RNFLT measurements decreased significantly over time for both the progressing (-0.97 µm/yr, P<0.001) and the contralateral non-progressing eyes (-0.71 µm/yr, P<0.001). Rates of RNFLT loss in the contralateral non-progressing eyes of progressing patients were significantly greater than rates of change in patients in whom none of the eyes progressed (-0.71 µm/yr vs. -0.25 µm/yr, respectively; P<0.001).

Conclusions: : There was a significant intereye correlation in the rate of RNFLT loss for glaucoma and glaucoma suspect patients. The rate of RNFLT loss in the nonprogressing eyes of patients showing only unilateral progression by conventional methods was significantly faster than in those patients with no progression in either eye. This suggests that patients with clinical progression in one eye may have progression in the contralateral eye that is detectable by GDx ECC but not yet by conventional methods.

Keywords: nerve fiber layer • ganglion cells 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept